Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

Clicks: 449
ID: 115341
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #5 of 85 articles by views in inflammatory bowel diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Vedolizumab is superior to placebo as induction and maintenance therapy for ulcerative colitis. Future studies are needed to define long-term efficacy and safety of this agent.
Reference Key
mh2015inflammatoryvedolizumab Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mosli MH;MacDonald JK;Bickston SJ;Behm BW;Tsoulis DJ;Cheng J;Khanna R;Feagan BG;;
Journal inflammatory bowel diseases
Year 2015
DOI
DOI not found
URL
https://www.pubmed.gov/25844963/
Keywords
systematic review meta-analysis National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine prognosis research support non-u.s. gov't Remission Induction Antibodies Monoclonal Brian G Feagan Humanized / therapeutic use* Colitis Ulcerative / drug therapy* Gastrointestinal Agents / therapeutic use* induction chemotherapy maintenance chemotherapy pmid:25844963 doi:10.1097/mib.0000000000000396 mahmoud h mosli john k macdonald

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.